Home › Compare › BCNN vs ABBV

BCNN vs ABBV: Dividend Comparison 2026

BCNN yields 153846.15% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BCNN wins by $3.570817397657267e+28M in total portfolio value
10 years
BCNN
BCNN
● Live price
153846.15%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3.570817397657267e+28M
Annual income
$35,662,574,083,913,823,000,000,000,000,000,000.00
Full BCNN calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — BCNN vs ABBV

📍 BCNN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBCNNABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BCNN + ABBV cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
BCNN pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BCNN
Annual income on $10K today (after 15% tax)
$13,076,923.08/yr
After 10yr DRIP, annual income (after tax)
$30,313,187,971,326,747,000,000,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, BCNN beats the other by $30,313,187,971,326,747,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BCNN + ABBV for your $10,000?

BCNN: 50%ABBV: 50%
100% ABBV50/50100% BCNN
Portfolio after 10yr
$1.7854086988286334e+28M
Annual income
$17,831,287,041,956,911,000,000,000,000,000,000.00/yr
Blended yield
99.87%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

BCNN
No analyst data
Altman Z
-7.4
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BCNN buys
0
ABBV buys
0
No recent congressional trades found for BCNN or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBCNNABBV
Forward yield153846.15% ✓3.12%
Annual dividend / share$2.00$6.65 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6% ✓
Portfolio after 10y$3.570817397657267e+28M$104.7K ✓
Annual income after 10y$35,662,574,083,913,823,000,000,000,000,000,000.00 ✓$25,725.73
Total dividends collected$3.5705187474861104e+28M$63.0K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BCNN vs ABBV ($10,000, DRIP)

YearBCNN PortfolioBCNN Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$15,395,315$15,384,615.38$11,559$438.51+$15.38M → BCNN
2$22,152,081,017$22,135,608,029.64$13,494$640.86+$22152.07M → BCNN
3$29,790,603,453,124$29,766,900,726,435.82$15,951$945.97+$29790603.44M → BCNN
4$37,444,193,407,360,220$37,412,317,461,665,380.00$19,152$1,413.89+$37444193407.34M → BCNN
5$43,987,751,239,956,050,000$43,947,685,953,010,180,000.00$23,443$2,146.38+$43987751239956.03M → BCNN
6$48,297,311,048,679,450,000,000$48,250,244,154,852,700,000,000.00$29,391$3,321.96+$48297311048679448.00M → BCNN
7$49,563,274,505,183,440,000,000,000$49,511,596,382,361,350,000,000,000.00$37,948$5,265.87+$49563274505183444992.00M → BCNN
8$47,538,442,557,656,110,000,000,000,000$47,485,409,853,935,560,000,000,000,000.00$50,795$8,596.74+$4.753844255765611e+22M → BCNN
9$42,616,722,111,071,980,000,000,000,000,000$42,565,855,977,535,280,000,000,000,000,000.00$71,034$14,549.41+$4.261672211107198e+25M → BCNN
10$35,708,173,976,572,667,000,000,000,000,000,000$35,662,574,083,913,823,000,000,000,000,000,000.00$104,715$25,725.73+$3.570817397657267e+28M → BCNN

BCNN vs ABBV: Complete Analysis 2026

BCNN — Stock

Tekumo LLC designs and develops on-demand service as a service (SaaS)-based platform. The company was founded in 2018 and is based in Colorado Springs, Colorado.

Full BCNN Calculator →

ABBV — Healthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this BCNN vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BCNN vs SCHDBCNN vs JEPIBCNN vs OBCNN vs KOBCNN vs MAINBCNN vs JNJBCNN vs MRKBCNN vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.